Fox Run Management L.L.C. acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 2,753 shares of the medical research company's stock, valued at approximately $541,000.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in IQV. FMR LLC raised its position in IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock worth $684,213,000 after acquiring an additional 804,963 shares during the period. Cantillon Capital Management LLC increased its stake in shares of IQVIA by 12.3% during the fourth quarter. Cantillon Capital Management LLC now owns 2,066,144 shares of the medical research company's stock worth $406,018,000 after purchasing an additional 226,017 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after purchasing an additional 583,396 shares during the last quarter. Nordea Investment Management AB lifted its stake in IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock valued at $277,908,000 after buying an additional 452,029 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in IQVIA by 3.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,246,890 shares of the medical research company's stock worth $245,026,000 after buying an additional 44,991 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.
IQVIA Trading Down 2.7 %
NYSE IQV traded down $5.04 during trading on Tuesday, hitting $181.07. The stock had a trading volume of 1,566,007 shares, compared to its average volume of 1,241,421. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a market capitalization of $31.93 billion, a PE ratio of 24.14, a PEG ratio of 1.99 and a beta of 1.50. The firm has a 50 day moving average price of $194.58 and a 200 day moving average price of $207.73. IQVIA Holdings Inc. has a twelve month low of $179.28 and a twelve month high of $253.84.
IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.
Analyst Ratings Changes
Several research firms have recently weighed in on IQV. StockNews.com downgraded IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. UBS Group decreased their price objective on IQVIA from $260.00 to $255.00 and set a "buy" rating on the stock in a report on Friday, February 7th. JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a report on Tuesday, February 18th. BTIG Research downgraded shares of IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Finally, Bank of America dropped their price objective on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating for the company in a research note on Friday, December 13th. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $249.05.
Check Out Our Latest Stock Report on IQVIA
IQVIA Company Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Read More
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
